Medikine

Our Mission.
Medikine, Inc. is a privately-held, discovery-stage biopharmaceutical company utilizing a proprietary drug discovery platform to identify drug candidates that slow the progression of, and potentially reverse, fibrosis associated with kidney disease.  Kidney fibrosis occurs in several chronic diseases such as diabetes, lupus, focal segmental glomerulosclerosis and genetic disorders such as Alport syndrome.  There are no FDA-approved drugs for kidney fibrosis.  Medikine's experienced management team is composed of scientist-entrepreneurs who have successfully worked together in previous companies to obtain financing, build teams, invent and employ drug discovery technologies, and develop drugs through human trials and FDA-approval.